ROKIT Healthcare teams up with WEGO to enter China’s $1 bil. skin regeneration market < Bio < Article

ROKIT Healthcare, a company specializing in organ regeneration technology, said Thursday it has signed a strategic partnership agreement with WEGO Group, one of China’s largest medical device companies, to expand its AI-based, hyper-personalized organ regeneration platform.

Amid renewed momentum in Korea–China economic cooperation following President Lee Jae Myung’s recent state visit to China, ROKIT Healthcare has emerged as one of the Korean companies seeking to leverage the improving bilateral climate. Through the partnership with WEGO Group, the company has laid the groundwork for entry into China’s estimated 1.4 trillion-won ($1 billion) skin regeneration market.

Beyond a conventional technology collaboration, ROKIT Healthcare said the agreement enables accelerated market access for its AI-driven long-term tissue regeneration technology in China.

Under the agreement, WEGO Group will oversee manufacturing, distribution, and regulatory procedures within China. ROKIT Healthcare said the partnership brings together its existing Chinese patents, supportive bilateral policy conditions, and WEGO’s established market presence.

Against this backdrop of growing Korea–China cooperation in AI-based bio-healthcare, ROKIT Healthcare plans to apply for China’s fast-track approval program, which significantly shortens the review process of the National Medical Products Administration (NMPA), the country’s medical device and pharmaceutical regulator. The company expects commercialization and initial revenue generation in the second half of this year, it said.

Based in Shandong Province, WEGO Group is China’s largest medical device and healthcare company by scale, operating a nationwide hospital and logistics network and often referred to as “China’s Johnson & Johnson.”

WEGO Group initiated the partnership during the state visit period, citing the competitiveness of ROKIT Healthcare’s AI-based organ regeneration platform, its multi-pipeline skin, cartilage, and kidney regeneration technologies, and its proprietary additive-free cryopreservation technology, which WEGO assessed as offering a strong competitive edge.

“The Chinese market is enormous. There are nearly 10 million patients with diabetic foot ulcers, burns, and skin cancer,” a WEGO official said. “Capturing just 10 percent of this market could generate more than $1 billion in revenue. This has the potential to become one of the largest single medical device cooperation deals involving a Korean Kosdaq-listed biotech company.”

A ROKIT Healthcare official said, “This collaboration with WEGO Group goes beyond a simple contract. It reflects how government-level diplomacy can translate into corporate opportunities. With core patents, China’s leading distribution partner, and regulatory cooperation in place, we expect meaningful growth in China from the second half of this year.”